Ottimo Pharma key facts
as of Oct 2026- Developer of cancer therapeutics designed to treat solid tumors.
- Ottimo Pharma is valued at approximately $242.4M as of Oct 2026 (last reported valuation).
- It has raised $149.7M; the latest was Later Stage VC ($143.0M) in Dec 2024.
- Notable investors include Index Ventures, OrbiMed, The Invus Group, Samsara BioCapital, RTW Investments — 11 tracked in total.
- Status: Privately Held (backing).
Ottimo Pharma's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Ottimo Pharma: the Monday email on marks, rounds and moves
Ottimo Pharma funding rounds
No funding rounds for Ottimo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ottimo Pharma
11+Ottimo Pharma valuation
Ottimo Pharma's last reported valuation was $242 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
Ottimo Pharma investors
11 investors are on record for Ottimo Pharma, including Index Ventures, OrbiMed, The Invus Group and Samsara BioCapital.
About Ottimo Pharma
Developer of cancer therapeutics designed to treat solid tumors. The company offers a bi-functional antibody that targets both immune checkpoint inhibition and angiogenesis which are pathways involved in cancer growth, enabling healthcare professionals with a dual-pathway approach that has the potential to provide effective treatment for cancer patients by attacking the disease from multiple angles.
- Sector
- Healthcare
- HQ
- Sandwich, United Kingdom
- Founded
- 2017
- Employees
- 10
- Website
- ottimopharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.